Cronkhite–Canada syndrome
Rare syndrome of GI polyps, first described in 1955.
Cronkhite–Canada syndrome is a rare condition marked by numerous polyps in the digestive tract. It occurs sporadically, is not inherited, and has no known cause. About two-thirds of those affected are of Japanese descent, and it affects men and women in a 3:2 ratio. The syndrome was first described in 1955 by physician Leonard Wolsey Cronkhite Jr. and radiologist Wilma Jeanne Canada.
Polyps appear throughout the gastrointestinal tract, most often in the stomach and large intestine, then the small intestine, but they typically spare the esophagus. Biopsies show these polyps are hamartomas, and while the risk of them turning cancerous is generally low, such progression has been reported several times. Common symptoms include chronic diarrhea and protein-losing enteropathy. Additional features may involve ectodermal tissue problems like hair loss, nail atrophy, or skin pigmentation changes.
No specific test exists for diagnosis; it relies on the patient's symptoms and disease features.
Management centers on nutritional support, which can include dietary advice, supplements, tube feeding, or intravenous fluids. Proposed treatments include cromolyn sodium, prednisone, and medications such as histamine H2 receptor antagonists or proton pump inhibitors.
- Field
- Medicine
- Known for
- Characterizing Cronkhite–Canada syndrome
- Specialty
- Internal medicine (Cronkhite), Radiology (Canada)
- Year characterized
- 1955
Lore & Background
Cronkhite–Canada syndrome was characterized in 1955 by Leonard Wolsey Cronkhite Jr., an internal medicine physician, and Wilma Jeanne Canada, a radiologist. The syndrome is sporadic and idiopathic, meaning its cause remains unknown and it does not appear to be hereditary. About two-thirds of patients are of Japanese descent, and the male-to-female ratio is 3:2.
Polyps are found throughout the gastrointestinal tract, most frequently in the stomach and large intestine, followed by the small intestine, though they typically avoid the esophagus. Biopsy reveals them to be hamartomas, and while the possibility of progression to cancer is generally considered low, it has been reported multiple times. Chronic diarrhea and protein-losing enteropathy are often observed, along with possible ectodermal anomalies such as alopecia, nail atrophy, or skin pigmentation.
There is no specific diagnostic test; diagnosis is based on symptoms and features. Management focuses on nutritional support, including dietary guidance, supplements, tube feeding, or intravenous solutions. Proposed treatments include cromolyn sodium, prednisone, histamine (H2) receptor antagonists, or proton pump inhibitors.
Reader's Guide
Cronkhite–Canada syndrome holds significance as a rare, acquired gastrointestinal disorder with distinctive clinical features. Its characterization in 1955 by Cronkhite and Canada established a framework for recognizing a syndrome that, while uncommon, presents with a consistent pattern of hamartomatous polyps and ectodermal changes. The syndrome's idiopathic nature and sporadic occurrence underscore ongoing challenges in understanding its etiology. Its legacy lies in highlighting the intersection of gastrointestinal pathology with systemic manifestations, and in emphasizing the importance of nutritional support and symptomatic management in rare diseases. The reported low but documented risk of malignant progression continues to inform clinical surveillance.
Did You Know?
- About two-thirds of patients with Cronkhite–Canada syndrome are of Japanese descent.
- The syndrome is sporadic and does not appear to be hereditary.
- Polyps typically avoid the esophagus but are found most frequently in the stomach and large intestine.
- Possible collateral features include alopecia, atrophy of the nails, or skin pigmentation.
Frequently Asked Questions
Who is Cronkhite–Canada syndrome?
It is a rare, non-inherited condition defined by the growth of multiple polyps throughout the digestive tract. The syndrome was first identified in 1955 by physician Leonard Wolsey Cronkhite Jr. and radiologist Wilma Jeanne Canada.
What are Cronkhite–Canada syndrome's powers/role?
Its clinical 'signature' is the development of hamartomatous polyps across the stomach, large intestine, and small intestine, while characteristically leaving the esophagus untouched. Biopsies confirm these growths are hamartomas rather than true neoplasms.
Why is Cronkhite–Canada syndrome important?
It remains one of the rarest gastrointestinal syndromes, with roughly two-thirds of documented cases occurring in individuals of Japanese descent. It also affects men and women in a roughly 3:2 ratio, keeping it a subject of ongoing demographic and pathogenic research.
What's Cronkhite–Canada syndrome's origin story?
The syndrome entered medical literature in 1955 when internal-medicine specialist Leonard Wolsey Cronkhite Jr. and radiologist Wilma Jeanne Canada jointly described the constellation of GI polyps and associated findings. Their complementary specialties—clinical medicine and diagnostic imaging—gave the condition its enduring dual name.
More in Genetic disorders with OMIM but no gene 1-24
Spotted an error? Know more?
Reader corrections go straight into our review queue. Suggest an edit · How this site is sourced